No trade has been recorded for SAPL since 27 Oct 2023 — 1,120 days before 20 Nov 2026. The figures on this page are from that session.
SAPL Sanofi-Aventis Pakistan share price
Sanofi-Aventis Pakistan in one paragraph
Sanofi-Aventis Pakistan (SAPL) last traded at Rs 870.00 on 27 Oct 2023. Its market capitalisation is about Rs 8.4B. Sanofi-Aventis Pakistan is in the Pharmaceuticals sector.
Close · 27 Oct 2023 · Pakistan Stock Exchange · Vol 650 live
0.00 (0.00%)
No price history available for this symbol yet.
- 1 week
- +24.29%
- 1 month
- +24.64%
- 3 months
- +15.94%
- 6 months
- +24.29%
- Year to date
- −9.19%
- 1 year
- −22.66%
- 3 years
- +10.13%
- 5 years
- +0.07%
- Last price
- Rs 870.00
- 27 Oct 2023
- Change on the day
- 0.00%
- Rs 0.00
- Market cap
Market cap
What the whole company costs at today's price.
How it's worked out
Share price multiplied by every share in issue.
How to read it
It is the company's size, not its value. A big number does not mean the price is high against earnings, and a small one does not mean it is low — that is what the ratios below are for.
- Rs 8.4B
- as of 20 Nov 2026
- Price per rupee earned
Price per rupee earned
Rupees you pay for each rupee the company earned last year.
How it's worked out
Share price divided by earnings per share over the last twelve reported months.
How to read it
Lower only means something against something — the same company's history, its sector, or the market. On its own this ratio says very little, and it is blank when a company lost money.
- —
- Dividend yield
Dividend yield
Cash paid out over the last year as a percentage of today's price.
How it's worked out
Dividends per share over twelve months divided by the share price.
How to read it
A very high yield is often a warning, not a gift: it usually means the price fell. Check the payout ratio next to see whether earnings actually cover it.
- —
- Earnings per share
- Rs 17.29
- the year to 31 Dec 2022
- 52-week range
- —
- Day range
- —
- prev close 870.00
- Volume
- 650
- shares, this session
- Avg volume (30d)
Average volume
Shares changing hands on a typical day.
How it's worked out
The mean daily volume over thirty sessions.
How to read it
Shares, not rupees — a million shares of a Rs 3 stock is a small market. "Traded per session" is the version in money.
- 612
6 more figures
- Book value / share
- Rs 523.72
- accounts to 31 Dec 2022
- Shares outstanding
- 9.6M
- Free float
Free float
The shares that can actually be bought and sold.
How it's worked out
Total shares minus the blocks held by sponsors, the government and other locked-in holders, as the exchange reports them.
How to read it
The float, not the market cap, is what sets how easily a real position can be built or unwound.
- 964K
- 10% of shares
- Last results filed
- 23 Oct 2023
- Sector
- Pharmaceuticals
- Shariah
- —
Figures as of 27 Oct 2023.
There is no SuperX note for Sanofi-Aventis Pakistan yet. A note is written after a market close.
01Returns1 year −22.66%
02ValueAgainst the sector
The same ratio on other definitions
SAPL earnings per share: Rs 17.29 · unconsolidated · the year to 31 Dec 2022 · PSX company page
Price per rupee earned, our own: 50.32 (870.00 on 27 Oct 2023 over 17.29, unconsolidated, the year to 31 Dec 2022)
Brokers’ price targets
Brokers’ 12-month price targets for SAPL, not SuperX’s
Collected from sell-side research notes. The figures here are the brokers’.
No broker covers SAPL in our records. Brokers cover 49 PSX companies and rate 47 of them buy.
03Grades and checksGrades A to F
04ResultsBy year and by quarter
Sales, profit and earnings per share, by year
What are SAPL’s sales, profit and earnings per share?
Annual figures from the accounts filed with PSX. Amounts in rupees; earnings per share (EPS) in rupees a share.
| FY (December) | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Sales | Rs 18.6B | Rs 15.9B | Rs 14.1B | Rs 14.5B |
| Profit after Taxation | Rs 167M | Rs 906M | Rs 493M | Rs 155M |
| EPS | Rs 17.29 | Rs 93.93 | Rs 51.12 | Rs 16.05 |
| EPS Growth | −81.6% | +83.7% | +218.5% | −74.7% |
| Gross Profit Margin | 26.2% | 26.0% | 27.0% | 25.7% |
| Net Profit Margin | 0.9% | 5.7% | 3.5% | 1.1% |
05AccountsCash, debt and the balance sheet
Balance sheet and returns
Sanofi-Aventis Pakistan balance sheet and returns
Return on equity, book value, gearing and margins for Sanofi-Aventis Pakistan, from the company’s own audited annual report. Figures for the year ended 31 Dec 2022, 10 months old.
- Return on equity
Return on equity
What the company earned on the shareholders' own money.
How it's worked out
Profit after tax divided by total equity, both from the balance sheet in the company's latest annual report. PSX publishes no balance sheet, so this is read out of the filing itself.
How to read it
The headline test of whether management is any good. Above about 20% is high for PSX; below the rate a bank deposit pays means the business earns less than doing nothing. Blank on negative equity, where the number flatters instead of informing.
- 3.31%
- Return on assets
Return on assets
Earnings against everything the company controls, not just what shareholders put in.
How it's worked out
Profit after tax divided by total assets, from the annual report's balance sheet.
How to read it
Read it beside return on equity. A wide gap between the two is borrowed money doing the work — on a bank or a leasing company, that gap is the whole story.
- 1.35%
- Book value / share
- Rs 523.72
- Price to book
Price to book
What the market charges for each rupee of net assets.
How it's worked out
Share price divided by book value per share.
How to read it
Under 1 means the market values the whole company at less than the net assets on its own balance sheet. On PSX that is common and is sometimes a bargain and sometimes a warning — check why.
- 1.66×
- Current ratio
Current ratio
Can it pay the bills due inside a year?
How it's worked out
Current assets divided by current liabilities, from the annual report.
How to read it
Under 1 means more falls due within a year than the company expects to collect within one. Not fatal on its own — but it is the first place to look when a company is in trouble.
- 1.41×
- Liabilities to equity
Liabilities to equity
How much is owed against how much is owned outright.
How it's worked out
Total liabilities divided by total equity. The broad measure — all liabilities, not only interest-bearing borrowings — because that is what the published tables reliably carry.
How to read it
Leverage magnifies both directions. High gearing is normal for banks and leasing, alarming for a manufacturer in a high-rate year like Pakistan has had.
- 1.44×
- Funded by shareholders
Funded by shareholders
The share of the balance sheet shareholders actually paid for.
How it's worked out
Total equity as a percentage of total assets — the plain-English complement of leverage.
How to read it
The higher it is, the less the company depends on lenders staying friendly. At Pakistani interest rates that dependence has cost a great deal.
- 41%
- Gross margin
Gross margin
What's left of each sales rupee after the cost of making the thing.
How it's worked out
Gross profit as a percentage of sales, from the annual report.
How to read it
Pricing power in one number. A margin that holds while the rupee falls means the company can pass costs on; one that shrinks means it cannot.
- 26.24%
- Operating margin
Operating margin
What's left of each sales rupee after running the business.
How it's worked out
Operating profit as a percentage of sales — after overheads, before interest and tax.
How to read it
The cleanest view of the business itself, stripped of how it is financed and taxed.
- 4.17%
- Effective tax rate
Effective tax rate
The share of pre-tax profit that actually went to the FBR.
How it's worked out
Taxation divided by profit before tax, from the annual report. Blank on a pre-tax loss, where the ratio inverts and means nothing.
How to read it
Pakistan's headline corporate rate plus super tax means many companies pay far more than 29%. A rate well above peers is a real drag on what reaches shareholders.
- 77%
| Year ended | Total assets | Equity | Revenue | Profit | Return on equity |
|---|---|---|---|---|---|
| 31 Dec 2022accounts not labelled | Rs 12.3B | Rs 5.1B | Rs 18.6B | Rs 167M | 3.3% |
| 31 Dec 2021accounts not labelled | Rs 9.3B | Rs 5.2B | Rs 15.9B | Rs 906M | 17.4% |
| 31 Dec 2020accounts not labelled | Rs 8.7B | Rs 4.7B | Rs 14.1B | Rs 493M | 10.5% |
| 31 Dec 2019accounts not labelled | Rs 7.7B | Rs 3.9B | Rs 14.5B | Rs 155M | 4.0% |
| 31 Dec 2018accounts not labelled | Rs 7.8B | — | Rs 13B | Rs 613M | — |
| 31 Dec 2017accounts not labelled | Rs 6.6B | Rs 4.1B | Rs 12.4B | Rs 1B | 24.3% |
Source: Sanofi-Aventis Pakistan’s annual report, page 112. Every figure above can be checked against it.
06DividendsEvery payout
Every payout
SAPL dividends and corporate actions
PSX quotes payouts as a % of the Rs 10 face value — 25% = Rs 2.50 per share. Unconfirmed ex-dates are marked “expected”.
| Type | % of face | Per share | Ex-date | Book closure | Qualify by |
|---|---|---|---|---|---|
| No dividends or corporate actions on record for SAPL. | |||||
No matches.
07Peers6 companies
Peers table
Other Pharmaceuticals stocks on PSX
Other companies in the same PSX sector, including its largest.
| Symbol | Company | Price | Chg % | Mkt cap | Price/earnings |
|---|---|---|---|---|---|
| SEARL | The Searle Company Limited | 79.69 | +0.18% | Rs 46.9B | 12.1× |
| WYETH | Wyeth Pakistan Limited | 2,007.70 | 0.00% | — | |
| ABOT | Abbott Laboratories (Pakistan) Limited | 1,013.28 | +0.42% | Rs 99.2B | 10.7× |
| GLAXO | GlaxoSmithKline Pakistan Limited | 332.02 | −0.92% | Rs 106B | 9.6× |
| HALEON | Haleon Pakistan Limited | 687.73 | 0.00% | Rs 80.5B | 12.3× |
| HINOON | Highnoon Laboratories Limited | 976.84 | +1.74% | Rs 51.8B | 12.6× |
No matches.
5 of 6 companies shown have a price-to-earnings ratio in Pharmaceuticals; a blank cell means a loss or no ratio. Each ratio is the one printed on that company’s own page.
08Price position52-week range and readings
09OwnersWho owns the shares
About the company
About Sanofi-Aventis Pakistan Limited
The Company was incorporated in Pakistan in 1967 as a Public Limited Company under Companies Act, 1913 (now Companies Act, 2017). The Company is a subsidiary of Sanofi Foreign Participations B.V. registered in Netherlands. The ultimate parent of the Company is Sanofi S.A., France. The Company is engaged in the manufacturing, selling and trading of pharmaceutical and related products.
- Sector
- Pharmaceuticals
- Website
- www.sanofi.com.pk
- Head office
- Plot No 23, Sector 22 Korangi Industrial Area Karachi, Pakistan.
- Auditor
- A. F. Ferguson & Co. Chartered Accountants
- Share registrar
- FAMCO Associates (Pvt) Ltd 8-F, Next to Hotel Faran, Nursery, Block -6, P.E.C.H.S Shahrah e Faisal Karachi
- Fiscal year end
- December
10Dated record22 dated events
The dated record
SAPL’s dated record
The exchange’s own record and ours: ex-dividends, book closures, results, every session move of 3% or more with the reason written out, the notices that move a price, and the news about Sanofi-Aventis Pakistan. Dates that have not happened are kept apart from dates that have, and each one says whether it was announced or projected.
Earlier · 22
Notice 20 notices, 26 Aug 2021 to 23 Oct 2023 open
- 23 Oct 2023 Financial results Financial Results for the Period Ended September 30, 2023
- 13 Oct 2023 Board meeting BOARD MEETING AND ANNOUNCEMENT OF CLOSED PERIOD
- 25 Aug 2023 Financial results Financial Results for the Half Year Ended June 30, 2023
- 17 Aug 2023 Board meeting BOARD MEETING AND ANNOUNCEMENT OF CLOSED PERIOD
- 30 May 2023 Financial results Financial Results for the Period Ended March 31, 2023
- 23 May 2023 Board meeting BOARD MEETING FOR THE PERIOD ENDED MARCH 31, 2023
- 20 Apr 2023 Financial results Financial Results for the Year Ended December 31, 2022
- 19 Apr 2023 Board meeting Board Meeting In Progress
- 12 Apr 2023 Board meeting Board Meeting for the year ended December 31, 2022
- 27 Oct 2022 Financial results Financial Results for the Period Ended September 30, 2022
- 19 Oct 2022 Board meeting Board Meeting for the period ended September 30, 2022
- 25 Aug 2022 Financial results Financial results for the half year ended June 30, 2022
- 17 Aug 2022 Board meeting Board Meeting for the half year ended June 30, 2022
- 28 Apr 2022 Financial results Financial Results for the Quarter Ended March 31, 2022
- 19 Apr 2022 Board meeting Board Meeting for the Quarter ended March 31, 2022
- 25 Mar 2022 Financial results Financial Results for the Year Ended December 31, 2021
- 17 Mar 2022 Board meeting Board Meeting for the Year ended December 31, 2021
- 27 Oct 2021 Financial results Financial Results for the Period Ended September 30, 2021
- 14 Oct 2021 Board meeting Board Meeting for the Period Ended September 30, 2021
- 26 Aug 2021 Financial results Financial Results for the Six Months Ended June 30, 2021
Results 2 results filings, 23 Oct 2023 to 21 Aug 2026 open
- 21 Aug 2026 Half-year results expected between 21 Aug 2026 and 31 Aug 2026 projected A window from past filings, not a date the company gave.
- 23 Oct 2023 Nine-month results, to 30 Sep 2023
Showing the most recent notices. Every ex-dividend, book closure, results filing and ticker change is listed.
Dates and events on this page are read as of 20 Nov 2026.
11QuestionsQuick answers
SAPL share price: quick answers
What is the Sanofi-Aventis Pakistan (SAPL) share price?
Sanofi-Aventis Pakistan (SAPL) last traded at Rs 870.00 on 27 Oct 2023.
What is SAPL's dividend yield?
No trailing dividend yield is shown for Sanofi-Aventis Pakistan Limited (SAPL) as of 27 Oct 2023. Check the dividend history table on this page for declared payouts.
How much does SAPL cost for each rupee it earns?
SuperX cannot price SAPL against its earnings as of 27 Oct 2023, because the trailing twelve months show no profit to divide by — the earnings are negative or not yet reported. See the financials table for reported earnings per share.
Is SAPL Shariah compliant?
No Shariah screening status is shown for SAPL as of 27 Oct 2023.
Where is the head office of Sanofi-Aventis Pakistan?
The head office of Sanofi-Aventis Pakistan (SAPL) is at Plot No 23, Sector 22 Korangi Industrial Area Karachi, Pakistan (PSX company page, 7 Nov 2026).
Who is the auditor of Sanofi-Aventis Pakistan?
The auditor of Sanofi-Aventis Pakistan (SAPL) is A. F. Ferguson & Co. Chartered Accountants (PSX company page, 7 Nov 2026).
Who is the share registrar of Sanofi-Aventis Pakistan?
The share registrar of Sanofi-Aventis Pakistan (SAPL) is FAMCO Associates (Pvt) Ltd 8-F, Next to Hotel Faran, Nursery, Block -6, P.E.C.H.S Shahrah e Faisal Karachi (PSX company page, 7 Nov 2026).
When does the financial year of Sanofi-Aventis Pakistan end?
The financial year of Sanofi-Aventis Pakistan (SAPL) ends in December (PSX company page, 7 Nov 2026).
How many shares of Sanofi-Aventis Pakistan are outstanding?
Sanofi-Aventis Pakistan (SAPL) has 9,644,800 shares outstanding (PSX company page, 7 Nov 2026).
What is the free float of Sanofi-Aventis Pakistan?
The free float of Sanofi-Aventis Pakistan (SAPL) is 10% of its shares (PSX company page, 7 Nov 2026).
What does Sanofi-Aventis Pakistan do?
The company profile on PSX (7 Nov 2026) reads: The Company was incorporated in Pakistan in 1967 as a Public Limited Company under Companies Act, 1913 (now Companies Act, 2017). The Company is a subsidiary of Sanofi Foreign Participations B.V. registered in Netherlands.
Answers use the facts on this page. Prices are as of 27 Oct 2023.
12SourcesGuides, filings and sources
Guides for SAPL
Plain explanations of the figures on this page.
Filings and reports
Sanofi-Aventis Pakistan filings and reports
43 documents Sanofi-Aventis Pakistan has published — annual reports, quarterly accounts and briefing decks. PSX filings are marked PSX; the rest come from the company’s own investor relations page. Links open the original PDF at the source.
Annual reports · 10
- Annual report 2022 Company
- Annual report 2021 Company
- Annual report 2020 Company
- Annual report 2019 Company
- Annual report 2018 Company
- Annual report 2017 Company
- Annual report 2016 Company
- Annual report 2015 Company
and 2 more
Half-yearly accounts · 1
Quarterly accounts · 31
- Quarterly report 2023 PSX
- Quarterly report 2023 PSX
- Quarterly report 2023 PSX
- Quarterly report 2022 Company
- Quarterly report 2022 Company
- Quarterly report 2022 Company
- Quarterly report 2021 Company
- Quarterly report 2021 Company
and 23 more
Financial results · 1
Data from PSX via SuperX, delayed and provided for information only — not investment advice. Figures may contain errors; verify with your broker before acting. As of .
Track SAPL in your portfolio, from 23 December
Trade logging, price alerts and smart-money flows for PSX investors. Join the waitlist and we email once, when it is ready.
SuperX is not a broker and not an adviser. It never places an order and never asks for a broker login.
